Source comparison
Zadaxin Same as Thymosin Alpha-1: Regulatory and Market Comparison
Amino Acid Sequence 28-residue acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH) Identical 28-residue sequence Molecularly indistinguishable. Same peptide Synthesis Method Solid-phase peptide synthesis (SPPS) under cGMP SPPS under ISO-certified facilitie
This comparison does not assign a generated winner or score.
- Amino Acid Sequence
- 28-residue acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH)
- Identical 28-residue sequence
- Molecularly indistinguishable. Same peptide
- Synthesis Method
- Solid-phase peptide synthesis (SPPS) under cGMP
- SPPS under ISO-certified facilities (reputable suppliers)
- Same method, quality depends on facility oversight
- Purity Standard
- >98% via HPLC, <0.1 EU/mg endotoxin
- >98% HPLC (verified suppliers), endotoxin testing varies
- Identical purity when properly synthesized
- Regulatory Approval
- Approved in 35+ countries (not FDA-approved)
- No regulatory approval. Research use only
- Zadaxin has clinical approval; generics lack regulatory pathway
- Typical Cost
- $300–$500 per 1.6 mg vial (historical pricing)
- $80–$150 per 1.6 mg vial (research-grade)
- Generic offers 60–75% cost reduction without molecular difference
- Mechanism of Action
- TLR-2/TLR-9 binding → NF-κB activation → IL-2/IFN-γ upregulation
- Identical TLR-2/TLR-9 pathway
- Same receptor targets, same downstream signaling